BIONDVAX PHARMACEUTICALS LTD. is an Israeli biopharmaceutical company developing a universal influenza vaccine called M-001. BiondVax is a publicly traded company, listed on the NASDAQ. The vaccine technology was invented in the 1990s at the Weizmann Institute of Science in the laboratory of Ruth Arnon, and was licensed to BiondVax in 2003. As of March 2019, the lead compound was in Phase III trial.
